VP Quality Assurance

Allucent launches IGNITE(TM) site network to enhance speed, quality, and predictability across clinical trial delivery. Jun 30, 2026 * Pre-qualified global site network aligned to Allucent's therapeutic Centers of Expertise (ACEs) * Defined execution commitments for feasibility, startup, and enrollment * Built on strategic site partnerships to reduce risk and improve trial predictability CARY, N.C., June 30, 2026 - Allucent, a global specialty CRO purpose-built for small and mid-sized biopharma, today announced the launch of its Integrated Global Network for Innovative Trial Execution (IGNITE(TM). A performance-based global network that will encompass more than 250 pre-qualified clinical research sites, IGNITE is built to improve study predictability, accelerate site activation and patient recruitment, and reduce development risk. The IGNITE network boosts Allucent's global site ecosystem by connecting sponsors with high-performing research sites aligned with Allucent's ACEs across oncology and hematology, neuroscience, cardiometabolic diseases, immunology & inflammation, infectious diseases, and rare diseases. Built on long-term strategic partnerships rather than study-by-study site selection, IGNITE brings together specialist investigators, established site relationships, and deep therapeutic expertise to advance complex clinical programs. Designed to strengthen and streamline execution from study startup through enrollment, IGNITE provides sponsors with accelerated feasibility assessments, including responses within 72 hours, and access to pre-qualified sites committed to defined timelines. These commitments include site activation within 60 days of final protocol in North America and within 3-4 weeks following regulatory approvals outside North America, enabling sponsors to move efficiently from protocol approval to patient screening. IGNITE supports study execution from the first patient in through the last patient enrolled, helping sponsors reduce variability and anticipate challenges earlier to maintain trial momentum. Unlike traditional site networks, IGNITE is built around mutual accountability between sponsors, CRO teams, and participating sites. Site partners benefit from earlier study engagement, streamlined processes, and access to trials aligned with their expertise, while sponsors gain access to experienced investigators and patient populations representing more than 50 million individuals across therapeutic areas relevant to their studies. Together, these advantages create a more responsive and collaborative model for trial delivery. "Today's development environment demands more than access to sites, it requires confidence in execution," said Patrick Phillips, chief operating officer of Allucent. "IGNITE brings together proven site partners, therapeutic expertise, and clear operational commitments to help sponsors move from protocol to patient enrollment faster and with greater predictability. It's a differentiated approach that creates stronger alignment across sponsors, sites, and patients, helping reduce execution risk and improve trial predictability." "Strong enrollment outcomes start with selecting the right sites and engaging them early," said Almenia Garvey, senior director, global feasibility, site and patient engagement, Allucent. "Through IGNITE, we're building deeper partnerships with sites that share our commitment to quality, responsiveness, and performance. That means sponsors can move studies forward with greater confidence, reaching milestones faster and keeping programs on track when it matters most." The launch of IGNITE further strengthens Allucent's specialty CRO model, bringing together therapeutic expertise, technology and AI, site strategy, and global trial execution to help emerging biopharma companies navigate increasingly complex development programs. About Allucent Allucent is a global, tech-enabled, specialty CRO built for small and mid-sized biopharma companies tackling complex science. Allucent's integrated approach spanning clinical pharmacology, regulatory strategy, quantitative sciences, and global trial operations is delivered by an A-team of former regulators, leading scientists, and senior clinical experts. With 1,090+ studies conducted across 75+ countries and more than 155,000 patients, Allucent's combination of global reach plus deep expertise across complex and rare indications enables partners to move faster, reduce risk, and reach critical milestones with confidence. Visit Allucent.com for more information.

Allucent, a global specialty contract research organisation for small and mid-sized biopharma, has appointed new therapeutic strategy leaders across its Centers of Expertise, including oncology, neuroscience, cardiometabolic diseases, and immunology and inflammation. The company also named a head of advanced therapeutics covering rare disease and cell and gene therapy programmes. Brant Nicks joins as therapeutic strategy head for haematology and oncology, bringing over 30 years' experience. Roberta Anderson takes the neuroscience role with nearly 30 years in CNS clinical development. Long-tenured Allucent leaders Mila Grieg and Maria-Cruz Morillo were promoted to lead cardiometabolic and immunology, and advanced therapeutics, respectively. The appointments aim to strengthen Allucent's integrated drug development model, combining deep therapeutic expertise with operational execution.

Quantum BioPharma signs binding Letter of Intent with Allucent to conduct Phase 2 clinical trial in multiple sclerosis. * 2 hrs ago TORONTO, March 30, 2026 (GLOBE NEWSWIRE) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has entered into a binding Letter of Intent (LOI) with Allucent, a global contract research organization with extensive experience supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis (MS). This strategic partnership represents a significant milestone in Quantum BioPharma's clinical development pipeline and underscores the Company's commitment to advancing a potentially innovative solution for those MS patients suffering from debilitating mobility conditions unlike any solution in the market today. The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS. Quantum BioPharma expects to initiate the Phase 2 trial in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operational arrangements. Under the terms of the LOI, Allucent will provide comprehensive clinical trial services designed to support efficient execution and data integrity throughout the study: | Study Start-Up | Regulatory submissions, ethics approvals | Accelerated trial initiation | | Site Selection & Management | Global site network coordination | Optimal patient access | | Patient Recruitment | Enrollment strategy and execution | Efficient trial completion | | Data Management | Collection, analysis, reporting | Rigorous clinical data integrity | | Regulatory Support | Agency interactions, compliance | Streamlined development pathway | | / | / | / | The parties will finalize a more comprehensive and definitive services agreement in the coming weeks, solidifying this strategic partnership. First-in-Class Potential Therapeutic Innovation for MS Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination - a key driver of disease progression in MS. This innovative mechanism represents a differentiated therapeutic approach in the global MS market, where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration. "Lucid-MS is a First-in-Class, New Chemical Entity, Therapeutic Innovation designed to provide neuroprotection through the inhibition of demyelination, a key driver of disease progression in MS," said Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma. "This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration. This Phase 2 trial will evaluate efficacy, safety and tolerability, while exploring the relationship between this mechanism and established clinical and radiographic markers of disease activity." "We are pleased to engage Allucent, a global CRO with extensive experience in Phase 2 and Phase 3 central nervous system trials, including prior MS studies, as we advance our clinical program," said Zeeshan Saeed, CEO of Quantum BioPharma. "Their therapeutic expertise and global operational capabilities are expected to support the efficient execution of our Phase 2 trial. Our research continues to demonstrate the potential of this novel approach to transform MS patient outcomes." Why Allucent: Global CRO Excellence Allucent is a global, specialty contract research organization designed for small and mid-sized biopharma, delivering integrated clinical, regulatory, and operational expertise across complex programs, including neuroscience. Their proven track record in CNS and MS trials makes them an ideal partner for advancing Lucid-MS through Phase 2. | Deep CNS/MS Trial Experience | Disease-specific expertise | | Global Operational Footprint | Access to diverse patient populations | | Integrated Strategy & Execution | Efficient program delivery | | Regulatory Excellence | Streamlined agency interactions | | Data Management Rigor | High-quality clinical evidence | | / | / | "We're proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis," said Paula Brown Stafford, CEO of Allucent. "Our team brings deep experience in CNS and MS trials, along with an integrated model that aligns strategy and execution, helping ensure programs are delivered efficiently and with the rigor these complex studies demand." Market Opportunity and Growth Strategy Multiple sclerosis affects approximately 2.8 million people worldwide (source: https://pmc.ncbi.nlm.nih.gov Atlas of MS, Third Edition (PMC/NCBI)), representing a significant global healthcare challenge and substantial market opportunity for innovative treatments. The MS therapeutic market is projected to exceed $38 billion by 2030 according to Grand View Research www.grandviewresearch.com. Quantum BioPharma's differentiated approach - targeting demyelination directly - positions Lucid-MS to address current unmet patient needs and potentially capture meaningful market share in the emerging neuroprotective segment. About Quantum BioPharma Ltd. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. ("UWI"), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of December 31, 2025) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. About Allucent Allucent is a global, specialty CRO designed for small and mid-sized biopharma, delivering integrated clinical, regulatory, and operational expertise across complex programs, including neuroscience. Visit www.Allucent.com for more information. Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law. Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Telephone: (416) 854-8884 Investor Relations